The OPUS-3 phase 3 trial of lifitegrast has met its primary endpoint of improving patient-reported symptoms of dry eye disease, according to topline results released by Shire. OPUS-3, a phase 3 efficacy and safety study of lifitegrast vs. placebo, met its primary endpoint of significantly improving patient-reported symptoms from baseline to day 84 (P = .0007), according to a company press release. Patient symptoms significantly improved (P
NEW YORK — The HumanOptics artificial iris may be well-tolerated with improved cosmetic results compared with previous devices, according to a speaker here.In the past, surgeons could use fin devices inserted through a small incision, as well as IOL-iris diaphragm combinations.
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2015 financial results after the market close on Tuesday, November 10, 2015. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on Nov
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics will report third quarter 2015 financial results on Wednesday, November 4, 2015 and host a conference call at 8:30 a.m. ET on that same day.
Antibiotic resistance remains high among ocular staphylococcal isolates. Nearly half are methicillin-resistant and are also more likely to be resistant to multiple antibiotics, a new study suggested. Medscape Medical News
Status: Completed,
Condition Summary: Dry Eye Disease